XML 32 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
Revenue Recognition (Tables)
 3 Months Ended
Mar. 31, 2018
Revenue from Contract with Customer [Abstract]  
Disaggregation of revenue
The following table provides information about disaggregated revenue from contracts with customers into the nature of the products and services, geographic regions, and includes a reconciliation of the disaggregated revenue with reportable segments. The geographic regions that are tracked are the Americas (United States, Canada, Latin America), EMEA (Europe, Middle East, Africa) and APAC (Australia, New Zealand, Southeast Asia, China).
 
Three months ended March 31, 2018
 
Three months ended March 31, 2017
(in thousands)
Performance Enzymes
 
 Novel Biotherapeutics
 
Total
 
Performance Enzymes
 
 Novel Biotherapeutics
 
Total
Major products and service:
 
 
 
 
 
 
 
 
 
 
 
Product Revenue
$
6,163

 
$
—

 
$
6,163

 
$
5,586

 
$
—

 
$
5,586

       Research and development
       revenue
4,566

 
3,313

 
7,879

 
2,385

 
—

 
2,385

Total revenues
$
10,729

 
$
3,313

 
$
14,042

 
$
7,971

 
$
—

 
$
7,971

 
 
 
 
 
 
 
 
 
 
 
 
Primary geographical markets:
 
 
 
 
 
 
 
 
 
 
 
Americas
$
3,597

 
$
—

 
$
3,597

 
$
1,788

 
$
—

 
$
1,788

EMEA
1,679

 
3,313

 
4,992

 
3,208

 
—

 
3,208

APAC
5,453

 
—

 
5,453

 
2,975

 
—

 
2,975

Total revenues
$
10,729

 
$
3,313

 
$
14,042

 
$
7,971

 
$
—

 
$
7,971
Contract with customer
The following table presents changes in the contract assets, deferred contract costs, and liabilities (in thousands):
 
March 31, 2018
 
Beginning balance
 
Additions
 
Deductions (1)
 
Ending balance
Contract Assets
$
—

 
$
1,556

 
$
(1,556
)
 
$
—

Contract Costs
239

 
—

 
(47
)
 
192

Contract Liabilities: Deferred Revenue
18,966

 
1,465

 
(7,383
)
 
13,048

(1) The asset or liability balances are presented as a net position per contract and accordingly the deductions column includes the netting effect of presenting each contract on a net position basis as either a net liability or asset.
During the three months ended March 31, 2018, we recognized the following revenues (in thousands):
Revenue recognized in the period from:
 
Amounts included in contract liabilities at the beginning of the period:
 
     Performance obligations satisfied
$
5,828

Changes in the period:
 
     Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods
—

     Performance obligations satisfied from new activities in the period - contract revenue
8,214

Total revenue
$
14,042

The following table shows the reconciliation of contract liabilities from what was disclosed in the Form 10-K for the year ended December 31, 2017 and gives effect to the modified retrospective adoption of the revenue guidance on January 1, 2018 (in thousands):
Deferred Revenue, balance at December 31, 2017
$
13,793

Changes in estimated consideration
—

Unsatisfied performance obligations
$
5,173

Deferred Revenue, balance at January 1, 2018
$
18,966
Performance obligation, expected timing of satisfaction
The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period, in thousands. The estimated revenue does not include contracts with original durations of one year or less, amounts of variable consideration attributable to royalties, or contract renewals that are unexercised as of March 31, 2018. We did not recognize any revenue from performance obligations satisfied in previous periods.

The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts.
(in thousands)
2018
 
2019
 
2020
 
2021 and Thereafter
Total
Product Revenue
$
597

 
$
2,568

 
$
1,631

 
$
1,623

$
6,419

Research and development revenue
6,154

 
475

 
—

 
—

6,629

Total
$
6,751

 
$
3,043

 
$
1,631

 
$
1,623

$
13,048
Impact of adoption on financial statements
In accordance with Topic 606, the disclosure of the impact of adoption to our unaudited condensed consolidated statements of operations and balance sheets was as follows (in thousands, except per share amounts):
 
Three Months Ended March 31, 2018
 
As reported
 
Adjustments
 
Balances without adoption of Topic 606
Revenues:
 
 
 
 
 
Product revenue
$
6,163

 
$
(2,515
)
 
$
3,648

Research and development revenue
7,879

 
(1,322
)
 
6,557

Total revenues
14,042

 
(3,837
)
 
10,205

Costs and operating expenses:
 
 
 
 
 
Cost of product revenue
3,825

 
(1,285
)
 
2,540

Research and development
7,178

 
(47
)
 
7,131

Selling, general and administrative
7,746

 
—

 
7,746

Total costs and operating expenses
18,749

 
(1,332
)
 
17,417

Loss from operations
(4,707
)
 
(2,505
)
 
(7,212
)
Interest income
71

 
—

 
71

Other expenses
(60
)
 
—

 
(60
)
Loss before income taxes
(4,696
)
 
(2,505
)
 
(7,201
)
Provision (benefit) from income taxes
(2
)
 
—

 
(2
)
Net loss
$
(4,694
)
 
$
(2,505
)
 
$
(7,199
)
 


 
 
 
 
Net loss per share, basic and diluted
$
(0.10
)
 
$
(0.05
)
 
$
(0.15
)
Weighted average common shares used in computing net loss per share, basic and diluted
48,385

 
 
 
48,385



 
March 31, 2018
 
As reported
 
Adjustments
 
Balances without adoption of Topic 606
Assets
 
 
 
 
 
Accounts Receivable
$
8,974

 
$
(1,064
)
 
$
7,910

Other non-current assets
470

 
(192
)
 
278

Liabilities
 
 
 
 
 
Other accrued liabilities
5,304

 
(1,522
)
 
3,782

Deferred revenue - current
7,518

 
1,933

 
9,451

Deferred revenue - non-current
5,529

 
(3,221
)
 
2,308

Stockholders' equity
 
 
 
 
 
Accumulated deficit
(324,291
)
 
1,554

 
(322,737
)